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Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF,
has been established as a therapeutic target in a subset of sarcomas and leukemias. Here, we used novel small molecule inhibitors
and degraders along with RNA interference to assess the dependency on BRD9 in the context of diverse hematological
malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM) model
systems. Following depletion of BRD9 protein, AML cells undergo terminal differentiation, whereas apoptosis was more prominent
in ALL and MM. RNA-seq analysis of acute leukemia and MM cells revealed both unique and common signaling pathways affected
by BRD9 degradation, with common pathways including those associated with regulation of inﬂammation, cell adhesion, DNA
repair and cell cycle progression. Degradation of BRD9 potentiated the effects of several chemotherapeutic agents and targeted
therapies against AML, ALL, and MM. Our ﬁndings support further development of therapeutic targeting of BRD9, alone or
combined with other agents, as a novel strategy for acute leukemias and MM.
Blood Cancer Journal (2022)12:110 ; https://doi.org/10.1038/s41408-022-00704-7

INTRODUCTION
Acute myeloid leukemia (AML), characterized by clonal expansion
of undifferentiated myeloid progenitor cells, is the most common
acute leukemia affecting adults, with an incidence of over 20,000
cases annually in the U.S. [1–3]. The prognosis for AML varies
depending on mutational drivers, karyotype complexity and age
of patient, with an overall survival (OS) rate at 5 years for patients
<55 years ranging from “favorable” (OS rate = 64%), to
“intermediate” (OS rate = 41%), to “adverse” (OS rate = 11%)
[1]. The incidence of AML rises with age, and older patients (>65
years), who comprise most newly diagnosed cases, often cannot
tolerate available therapies and have a particularly dismal
prognosis [3]. Thus, AML is a complex disease and remains an
unmet medical need. Recent drug approvals for patients
harboring gain-of-function mutations in FLT3 and IDH1/2 include
midostaurin, gilteritinib, ivosidenib & enasidenib, and suggest that
fundamental understanding of disease subtypes will drive the
development of targeted and more effective medicines.
New therapeutic approaches are also needed for non-AML
hematopoietic malignancies, including older patients afﬂicted
with acute lymphoblastic leukemia (ALL), and multiple myeloma
(MM). The majority of ALL cases, characterized by proliferation of
malignant, immature lymphatic blasts [4], occur in children and

are mostly curable; however, the prognosis for adults is poor due
at least in part to chemotherapy resistance and drug intolerance
[5]. MM, a cancer of clonal plasma cells, is the second most
common hematologic malignancy after lymphoma [6, 7]. Standard
treatments, including proteasome inhibitors and immunomodulatory drugs (IMiDs), have improved overall 5-year survival rates to
49–56% and still provide an opportunity for agents that could
provide durable remissions and cures [7].
Epigenetic dysregulation is directly associated with multiple
hematological cancers [8]. Mutations in DNMT3A, NPM1, CBFβ/
RUNX, splicing factors and the chromosome cohesion machinery
(STAG2, RAD21, SMC1A/3) [9] provide insight that myeloid
differentiation requires remodeling, at the level of chromosomes,
chromatin and/or gene control. Components of SWI/SNF chromatin remodeling complexes have also been identiﬁed as dependencies in AML, which may constitute a new treatment approach.
In particular, the bromodomain-containing protein 9 (BRD9), a
speciﬁc component of the non-canonical (nc-BAF/GBAF) mammalian SWI/SNF chromatin remodeling complex [10–12], is essential
to maintain the transformed phenotype of AML. AML cells
sensitive to loss of BRD9 undergo cell cycle arrest and
differentiate. While distinct SWI/SNF (BAF) complexes have been
described that additionally include canonical BAF (cBAF) and
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Fig. 1 The BRD9 degrader, QA-68-ZU81, shows increased potency and selectivity versus BRD9 inhibitors. A Structure-based drug design
evolves chemical matter from selective binding domain (BD) inhibitor, EA-89-YM35 (“EA-89”), to selective BD degrader, QA-68-ZU81 (“QA-68”).
X-ray co-crystal shows binding mode of EA-89 on BRD9 at 1.76 Angstroms making extended interactions across the surface of BRD9 with
thienopyridone docking into the acetyl lysine pocket. B The BRD9 degrader, QA-68, provides an >100-fold increase in potency versus the
matched inhibitor, EA-89. 7-day assay. C Effects of BRD9 degrader treatment on BRD9 expression in MV4-11 cells. D, upper panel Comparison
of effects of QA-68 and EA-89 on BRD9, c-MYC and c-MYB expression in SKM-1 cells. 24-h assay. D, lower panel Comparison of effects of QA-68
and dBRD9-A on BRD9 expression. 6-day assay. E–H Effects of QA-68 or dBRD9-A treatment on BRD9, c-Myc and c-Myb expression in MV4-11
(E), Kasumi-1-luc + (F), HEL (G) and K052 (H). 24-h assay.

polybromoBAF (PBAF), there appears to be a speciﬁc dependency
on BRD9 for the completion of myeloid differentiation in a subset
of AML cell lines. Therefore while the BAF complexes regulate key
steps in chromatin transactions required for cell fate decisions,
including transcription factor binding and gene expression, the
BRD9-containing BAF complex appears to play key roles in
myeloid leukemia. [10, 13–15].
Previous work identiﬁed nc-BAF subunits as synthetic lethal
targets in malignant rhabdoid tumors and synovial sarcoma that
harbor driver mutations in core components of SWI/SNF
complexes; these ﬁndings suggest that an essential role for
BRD9 reﬂects an interplay among these complexes arising from
these mutations [16]. As noted, BRD9 has also been found to be
important for AML cell proliferation [17, 18], despite the absence
of reported mutations in SWI/SNF subunits. This may reﬂect a
stage-speciﬁc dependence of BRD9 to maintain a myeloid
progenitor program, perhaps at the level of maintaining expression of a progenitor or oncogenic program as described [17–19].
A number of small-molecule inhibitors of BRD9, based on a
phenyl naphthyridone scaffold (BI7273 & BI9564), have been
found to inhibit proliferation of mouse and human AML cell lines
[17, 20]. Paradoxically, the bromodomain in BRD9 has been shown
to be an ineffectual drug target and degradation is required to
reproduce the dependency seen with shRNA and CRISPR screens
[21]. In this report, we describe a novel BRD9 bromodomain
inhibitor, EA-89-YM35 (or EA-89), and a degrader-based analog
(QA-68-ZU81, or QA-68) that incorporates the EA-89 warhead into
a cereblon (CRBN)-targeting proteolysis-targeting chimera (PROTAC), to compare the efﬁcacy of inhibition versus degradation to
the impact seen with BRD9 knock-down (KD) by RNA interference.
We also explore the potential for BRD9 targeting to enhance
antileukemic effects of chemotherapeutic agents and targeted

inhibitors as a novel therapeutic strategy for acute leukemia and
MM. Our ﬁndings indicate that the degradation of BRD9 results in
signiﬁcantly greater effects compared to bromodomain inhibitors,
as seen in AML as well in other hematologic malignancies.
MATERIALS AND METHODS
All materials and methods details are provided in the Supplementary Data
Section.

RESULTS
BRD9 degrader treatment leads to inhibition of AML cell line
proliferation
BRD9 has been identiﬁed as a target in human AML using genetic
screens [17]. To explore this further, we investigated the
antileukemic activity of a novel small molecule inhibitor of BRD9
as well as PROTACs, in which this warhead is incorporated into a
heterobifunctional degrader that directs ubiquitination and
degradation of BRD9. EA-89 is a potent and selective inhibitor
that binds to BRD9 in a novel way. The binding mode of EA-89
determined by X-ray crystallography reveals that the thienopyridone head group binds to the acetyl lysine pocket similar to other
known bromodomain chemotypes, forming a direct hydrogen
bond with the conserved Asn100. Propyl substitution off the
pyridone nitrogen accesses an adjacent induced hydrophobic
pocket while the tetrahydro-2H-thiopyran ring picks up additional
protein interactions, not observed with previous BI-based
PROTACs, on the opposite side of the acetyl lysine pocket
(Fig. 1A). QA-68, an IMiD-based derivative of EA-89, extends from
the piperidine nitrogen and includes a di-piperizine amide linker
with an alkyne bridge to an IMiD that serves as a CRBN anchor
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Fig. 2 BRD9 degrader treatment leads to inhibition of AML cell line proliferation. A–E Proliferation assays: AML cell lines treated with QA68 or dBRD9-A. 6-day assay. Proliferation studies shown are representative of independent studies performed at least twice for which similar
results were observed. F Effects of QA-68 (upper panel) and dBRD9-A (lower panel) on BRD9 expression in QA-68-sensitive and –insensitive
AML cell lines. 24-hour assay. G Effects of QA-68 on SKM-1 cell differentiation. 4-day assay. H Effects of QA-68 on SKM-1 cell cycle progression.
6-day assay.

(chemical synthesis details and information regarding EA-89
binding to BRD9 are provided in supplementary materials and
methods).
We compared the activity of these molecules to a previously
described potent and selective BRD9 inhibitor (non-degrader), BI7273 [20], against human leukemia cell lines MV4;11 (Bmyelomonocytic leukemia), EOL1 (eosinophilic leukemia),
MOLM13 (acute monocytic leukemia), OCI-AML3 (AML), HEL
(erythroleukemia), THP1 (acute monocytic leukemia) and SKNO1
(AML) (Fig. 1B). HCT116 (colorectal cancer) was included as an outof-lineage control, and JQ1, an established potent inhibitor of BET
family proteins BRD2, 3, 4, was included as an inhibitor of
bromodomain proteins with a distinct selectivity proﬁle. The
inhibitor, EA-89, (structure shown in Fig. 1A) produces a strongly
selective proﬁle across a subset of leukemia lines with no impact
on the viability of THP-1, HEL, or HCT116 (Fig. 1B). Interestingly,
the degrader, QA-68, provides an >100-fold increase in potency
over EA-89 (Fig. 1B) and robustly degrades BRD9 in AML cells (Fig.
1C–H). Of note, in addition to showing less activity toward HCT116 cells, QA-68 also shows less antileukemic activity against the
AML cell lines, HEL and THP-1, which suggests that QA-68 is not
perfectly selective for AML and shows differential potency. The
previously described inhibitor, BI-7273 [20], appears to be inactive
across all lines with the exception of SKNO1, whereas JQ1 is
potently antiproliferative across all lines, including the nonhematopoietic HCT116 (Fig. 1B).
dBRD9-A is a previously-described BRD9 degrader with activity
in leukemia [22]. We compared its activity to these novel BRD9
ligands against a panel of leukemia lines. QA-68 treatment led to a
concentration-dependent inhibition of proliferation of MV4-11,
SKM-1 and Kasumi-1-luc+ cells (IC50 = 1–10 nM for MV4;11 and
SKM-1, and IC50 = 10–100 nM for Kasumi-1-luc + ), whereas cell
lines, such as HEL, KO52 and THP-1, showed less sensitivity at up
to 6 days of treatment (Fig. 2A–E, Supplementary Fig. 1A–J). AML
cell lines were generally less sensitive to EA-89, however, exhibited
differential sensitivity to dBRD9-A (Fig. 2A–E, Supplementary Fig.
1A–E). A positive correlation was generally observed between the
extent to which BRD9 was degraded and the sensitivity of AML
cells to degrader treatment (Fig. 2F). However, this was not
observed in the KO52 cell line, as BRD9 was absent at 10 nM QA68, although there was no decrease in cell number at that dose
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(Fig. 2E). BRD9 degradation was observed in as little as 6 hours
(Fig. 1C) and persists through 24 hours (Fig. 1C–H) and was
sustained over 6 days of treatment (Fig. 1D, lower panel).
Based on previous reports [17], we investigated the effect of
targeted BRD9 degradation in AML on the transcription factors
c-MYC and c-MYB, both involved in myeloid cell growth,
differentiation and survival. Concomitant with BRD9 degradation
we observed decreases in c-MYC and c-MYB protein in MV4-11
cells, decreases in c-MYC only in Kasumi-luc+ cells, and decreases
in c-MYB only in SKM-1 cells (Fig. 1D–F). In contrast, there were
little to no changes in c-MYC or c-MYB expression in BRD9
degrader-treated HEL or KO52 cells (Fig. 1G, H).
Targeted loss of BRD9 protein in AML cells affects cell growth,
differentiation, and colony formation
BRD9 has previously been reported to maintain leukemia cells in a
proliferating and undifferentiated state [17]. We observed BRD9
degraders to induce differentiation of SKM-1 cells, in contrast to
the BRD9 inhibitor, EA-89, which had little effect on SKM-1
differentiation and was less potent in inhibiting cell proliferation
(Fig. 2G, Supplementary Fig. 2A, B, Supplementary Fig. 3A, B). In
addition, QA-68 (degrader) more effectively inhibited SKM-1 cell
cycle progression than EA-89 (Fig. 2H and Supplementary Fig. 2C).
Concentrations of QA-68 used in the differentiation and cell cycle
studies were sufﬁcient to degrade BRD9, and concentrations of
EA-89 used for these studies were sufﬁcient to decrease levels of
c-MYB, suggesting an active and on-target concentration range for
both drugs (Fig. 1D).
To validate BRD9 as a target important for viability and
differentiation of AML cells, we performed Crispr knockout (KO)
and doxycycline-induced knockdown (KD) of BRD9 in selected
AML cell lines. We observed a correlation between Crispr KO of
BRD9 or doxycycline-induced BRD9 KD and inhibition of AML cell
growth (Fig. 3A, B). In addition, doxycycline-induced BRD9 KD led
to inhibition of AML cell colony growth in a methylcellulose assay
(Fig. 3C). An alternative shRNA vector system using plko.1 GFP led
to induction of SKM-1 differentiation following KD of BRD9, as
measured by CD11b expression, and inhibition of SKM-1 cell
growth (Fig. 3D), as well as inhibition of MV4-11 cell proliferation
(Supplementary Fig. 4A, B). Importantly, BRD9 was selectively
targeted without any loss of BRD7, suggesting that effects of KD
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Fig. 3 Targeted loss of BRD9 protein in AML cells due to genetic ablation affects cell growth, differentiation, and colony formation. A KO
of BRD9 in MV4-11 cells correlates with inhibited cell proliferation. Asterisks represent statistical signiﬁcance. t-test: ShA:BRD9 KO clones
(P < 0.0001). B Inducible KD of BRD9 in SKM-1 cells correlates with inhibited cell proliferation. Asterisks represent statistical signiﬁcance. t-test:
shNT:shBRD9 KD clones (P < 0.0001). C Effects of doxycycline-inducible BRD9 KD on SKM-1 colony formation. 200 cells/mL/well were seeded
using MethoCult Classic (+cytokines) and colonies were counted 7 days postseeding. Colonies were counted in 2–3 wells and averages + /standard deviations were determined. (Left panel) Colony counts shown as bar graphs. Asterisks represent statistical signiﬁcance. t-test: SKM-1
control (-dox): SKM-1 control (+dox) (P = 0.237); SKM-1 BRD9 KD#2 (-dox):SKM-1 BRD9 KD#2 (+dox) (P = 0.0001); SKM-1 BRD9 KD#4
(-dox):SKM-1 BRD9 KD#4 (+dox) (P = 0.0001). (Right panel) Images of colonies. D Effects of BRD9 KD on SKM-1 cell differentiation (from a pool
of triplicates) (left panel), and growth (6 replicates for each time point) (middle panel). Y-axis shows percent GFP positive cells. (Right panel)
BRD9 and BRD7 expression in BRD9 KD cells versus nontarget KD control cells.

on growth and differentiation were on-target and due to BRD9
depletion. Taken together, our results conﬁrm a BRD9 dependency
in AML.
Targeted loss of BRD9 protein affects ALL cell growth and
viability
Given the observed importance of BRD9 for the viability and
growth of AML cells, we hypothesized that a BRD9 dependency
might similarly exist for other hematopoietic malignancies. To
address this, we tested the activity of BRD9 degraders, QA-68 and
dBRD9-A, on the growth and viability of a panel of human ALL cell
lines. All B-ALL cell lines that we tested showed different levels of
sensitivity to BRD9 degrader treatment: SEM, SEMK2, RS4;11, and
REH (IC50s in the range of 1–10 nM); 697 and p190BCR-ABLpositive SUP-B15 (IC50s close to 1 nM); NALM6 and RCH-ACV
(IC50s in the 10–100 nM range) (Fig. 4A, Supplementary Figs. 5A–E
and 6A–D). Drug treatment-induced BRD9 degradation correlated
with the drug sensitivity of the ALL cell lines: for example, partial
BRD9 degradation was observed in less BRD9 degrader-sensitive
NALM6 cells whereas BRD9 degradation was complete for more
BRD9 degrader-sensitive lines such as RS4;11 and SEM (Fig. 4A, B,
Supplementary Fig. 5A–E). As was observed with AML, the BRD9
degraders, QA-68 and dBRD9-A, showed higher potency against
the B- ALL lines than the BRD9 inhibitor, EA-89 (Supplementary
Fig. 5E, F, Supplementary Fig. 6A–D). BRD9 degrader effects on
c-MYC expression, similar to AML, were variable and modest
among the cell lines tested (Supplementary Fig. 5). In contrast to
the high BRD9 degrader sensitivity we observed for B-ALL lines,
human T-ALL cell lines, including PF-382, Jurkat, CCRF-CEM, DND41, HPB-ALL, KOPT-K1, and MOLT-4, were insensitive in terms of
growth inhibition (Supplementary Fig. 6E–L). BRD9 degrader
treatment led to G1 arrest in some B-ALL cell lines, and induction
of apoptosis in other cell lines (Fig. 4C, D and data not shown). Our
results collectively suggest that B-ALL is a hematopoietic

malignancy that is sensitive to BRD9 degrader treatment and
leads to a cytotoxic or cytostatic response.
To validate BRD9 as a target important for proliferation and
viability of ALL cells, we performed doxycycline-induced KD of
BRD9 in selected ALL cell lines. We observed a correlation
between doxycycline-induced BRD9 KD and inhibition of NALM6
and SEM cell line growth (Fig. 4E, F). These results are supportive
of a BRD9 dependency in ALL and introduce ALL as a novel
disease target for BRD9 degrader therapy.
To investigate the clinical potential of BRD9 targeting through
degradation or inhibition for ALL, we tested BRD9 degraders and
the BRD9 inhibitor, EA-89, against primary ALL cells (patient details
are provided in Supplementary Table 1). Primary ALL cells showed
more sensitivity to QA-68 and dBRD9-A than normal bone marrow
cells, and more potency than EA-89 against primary ALL cells
(primary ALL1 and primary ALL3) (Fig. 4G, H). In addition, QA-68
potentiated the effects of daunorubicin against primary ALL cells
and RS4;11 cells (tested as a control) (Fig. 4I and Supplementary
Fig. 7A, B).
Targeted loss of BRD9 protein inhibits primary AML cell
growth and colony formation
To assess the clinical potential of BRD9 targeting for AML, we
investigated the antileukemic activity of QA-68 and EA-89 against
primary AML cells (patient details provided in Supplementary
Table 1), using proliferation and colony formation assays (Fig. 5).
Primary AML cells (AML4), SKM-1 and MV4-11 cells, showed higher
sensitivity to QA-68 treatment than normal bone marrow cells and
thus, importantly, demonstrated a therapeutic window for QA-68
(Fig. 5A and Supplementary Fig. 7C). Consistent with AML cell
lines, QA-68 was more potent against primary sample AML4 than
EA-89 (Fig. 5A). When tested in colony formation assays, BRD9
degrader- or inhibitor-treated primary AML cells completely failed
to grow whereas colony formation with normal bone marrow-
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Fig. 4 Targeted loss of BRD9 protein inhibits ALL cell proliferation and cell cycle progression and decreases viability. A Proliferation
assays: ALL cell lines treated with QA-68. 6-day assay. B Effects of QA-68 on BRD9 expression in ALL cell lines. 24-h assay. C Effects of QA-68 on
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I Treatment of primary ALL-3 cells with QA-68 alone, doxorubicin alone, or a combination. 6-day assay.

derived cultures were decreased by a modest 2-fold effect
(Fig. 5B). In addition, treatment of normal peripheral blood
mononucleated cells (PBMCs) with QA-68 or the BRD2,3,4
inhibitor, JQ1, at concentrations up to 10 μΜ showed no
detectable cell loss by QA-68, while JQ1 produced a strong
viability phenotype (Fig. 5C). EA-89, while less toxic toward normal
PBMCs than JQ1, did however kill cells at higher concentrations
(5–10 μM). Coupled with the lack of toxicity of BRD9 degrader
treatment against normal bone marrow cells, our ﬁndings suggest
small molecule degradation of BRD9 is comparatively nontoxic
toward normal hematopoietic cells. Of note, QA-68 treatment
leads to degradation of BRD9, but not the JQ1 target, BRD4, in
leukemia cells, and washout of QA-68 leads to a reversal of BRD9
degradation effects but has no effect on BRD4 (Supplementary
Fig. 8A, B). Taken together, these results support the selectivity of
QA-68 toward BRD9 as a protein target.
QA-68 was observed to inhibit colony formation of additional
primary AML bone marrow and PBMC cells (Fig. 5D, E).
Interestingly, despite QA-68 and 5-azacytidine showing little
potency against one primary AML sample (AML14) as single
agents, the combination of QA-68 and 5-azacytidine was more
efﬁcacious, resulting in a leftward shift of the dose-response
curves (Fig. 5F).
Targeted loss of BRD9 protein in MM inhibits cell growth,
viability, cell cycle progression, and colony formation
We were interested in investigating other hematopoietic malignancies to determine what role, if any, BRD9 may play in growth
Blood Cancer Journal (2022)12:110

and viability. We treated several MM cell lines with QA-68, dBRD9A, and EA-89 and, similar to AML and ALL, we observed QA-68 or
dBRD9A to more potently inhibit cell proliferation than EA-89 with
a concomitant decrease in BRD9 protein (Fig. 6A, B and
Supplementary Fig. 9). Cell lines, including MM.1S and H929,
showed the highest sensitivity to BRD9 degrader treatment as
compared to other lines, such as U266 and 8226. QA-68- and
dBRD9-A-induced cell killing correlated with BRD9 degradation,
and as observed with AML and ALL, c-MYC expression was
variable in response to BRD9 loss in different MM lines
(Supplementary Fig. 9D, F). QA-68 or dBRD9-A treatment of MM
cell lines induced modest levels of apoptosis and inhibited cell
cycle progression (most apparent at 1000 nM) (Fig. 6C, D).
Doxycycline-induced BRD9 KD in H929 cells led to inhibited cell
proliferation and inhibition of colony formation, validating BRD9
as an important target for the growth and viability of MM cells
(Fig. 6E). Importantly, dBRD9-A selectively killed primary MM cells,
with little effect on bone marrow cells from a healthy donor
(patient details provided in Supplementary Table 1) (Fig. 6F).
Targeted inhibition or degradation of BRD9 potentiates the
antileukemic effects of standard chemotherapy and targeted
agents against acute leukemia and MM
The heterogeneity of AML, attributed to multiple factors, can
enable the establishment of leukemic clones with distinct
dependencies at different stages of myeloid differentiation
making AML a therapeutically challenging disease. Combination
therapy is an approach used to increase remissions across diverse
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Fig. 5 Targeted loss of BRD9 protein by degradation leads to inhibition of primary AML and ALL cell growth and colony formation.
A Proliferation assays: Normal bone marrow cells (sample #1) and primary AML4 cells (secondary AML) treated with QA-68 and EA-89. 6-day
assay. SKM-1 and MV4-11 cell lines were tested as positive controls (B) QA-68, EA-89 and dBRD9-A effects on normal bone marrow or primary
AML4 colony formation using MethoCult H4434 Classic methylcellulose medium (with cytokines) and IMDM culture media. SKM-1 cells were
tested as a positive control. Shown are colony counts taken following 8 days from the start of the assay. C Treatment of normal PBMCs with
QA-68 or EA-89 versus the BRD4 inhibitor, JQ1. 4-day assay. D Effects of QA-68 treatment on primary AML PBMCs (sample AML15) colony
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AML subtypes. We therefore investigated the ability of BRD9
targeting to potentiate agents that are the standard of care in
leukemia, such as decitabine, ATRA, and 5-azacytidine, as well as
more targeted agents, such as venetoclax and olaparib. We
observed QA-68, dBRD9-A, and EA-89 to display high synergizing
activity as measured by antiproliferative activity with the
observation that both degraders when combined with other
agents induce differentiation (Fig. 7A, B, Supplementary Fig. 10,
and Supplementary Fig. 11). The degree of synergy observed with
QA-68, as assessed by combination indices generated using Chou
and Talalay analysis [23], was stronger than that observed with
EA89 (Fig. 7A, B).
We next investigated the ability of BRD9 degrader treatment to
potentiate effects of standard of care therapy against ALL and MM.
We observed QA-68 or dBRD9-A to synergize with standard ALL
therapies, such as the anthracyclines daunorubicin and doxorubicin, against several B-ALL lines, including RS4;11, SEM, and
NALM6, as well as to synergize with pomalidomide against MM
cells (Fig. 7A, B). Together, our results support BRD9 targeting as a
potential therapeutic strategy for ALL and MM in combination
with standard of care agents.
BRD9 regulates common and lineage-dependent pathways in
heme malignancies, including those associated with cell cycle
progression, the inﬂammatory response, immune response,
cell adhesion, and DNA replication and repair
Using RNA-seq analysis, the global transcript perturbation proﬁle
after QA-68 or dBRD9-A treatment in MV4-11 cells, as a
representative of AML, was compared. Principal component
analysis of the dBRD9-A-treated group and the novel QA-68treated group accounts for over 80% of the variance when
compared to the DMSO treatment, while the inter-degrader group
variance <5% (Fig. 8A and Supplementary Fig. 12A). In addition to
AML, we compared the effects of QA-68 treatment (24 hr, 1 μM,
which is nontoxic to normal bone marrow cells) on gene

transcription in RS411 and H929 as representative of ALL and
MM lineages. We observed more pronounced perturbation (Fig.
8B) in gene expression by QA-68 treatment in MV4-11 and H929
than in RS4;11 (Fold change 1.5 and Benjamini-Hochberg False
discovery rate < 0.05). Geneset enrichment test in MV4-11 and
H929 was in agreement with previously published reports that
loss of BRD9 supported repression of the MYC pathway [17], while
induction of myeloid differentiation signatures like ITGAM, PRDM1,
TLR5, MAFB, FOS, CSF1R and ID2 (Fig. 8A–D and Supplementary
Fig. 12B) was unique to MV4-11. In all three hematopoietic
malignancies, we observe upregulation of Differentially Expressed
Genes (DEGs) enriched in biological processes associated with
signal transduction, inﬂammation, immune response, and cell
adhesion (Fig. 8C–E and Supplementary Fig. 12B). Downregulated
pathways in common among the three malignancies displayed
that BRD9 targeting perturbed the underlaying signatures critical
to cell survival in these diseases and included cell cycle
progression, and DNA repair and replication. Not unexpectedly,
the largest number of DEGs were non-overlapping and unique to
each of the three hematopoietic malignancies investigated (Fig.
8B). The analysis revealed 40 genes to be commonly downregulated in AML, ALL and MM, and 115 genes to be commonly
upregulated in the three malignancies (Fig. 8B). qPCR was
employed to validate the deregulation of selected genes in
response to BRD9 degrader treatment (Supplementary Fig. 12C–E).
DISCUSSION
BRD9, a subunit of the ncBAF SWI/SNF chromatin remodeling
complex, has previously been reported to be important for the
growth and viability of AML cells [17, 20], and BRD9-targeting
degraders have been developed and evaluated as a novel
therapeutic strategy for AML [21, 22, 24]. The main theme of the
current study is BRD9 as a therapeutic, druggable target in a select
panel of heme malignancies that includes and extends beyond
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(P = 0.2475); H929 BRD9 KD#2 (-dox):H929 BRD9 KD#2 (+dox) (P < 0.0001); H929 BRD9 KD#5 (-dox):H929 BRD9 KD#5 (+dox) (P < 0.0001).
E, upper left panel: t-test, 6-day: H929 control (-dox):H929 control (+dox) (P = 0.9899); H929 BRD9 KD#1 (-dox):H929 BRD9 KD#1 (+dox)
(P = 0.0004). E, upper right panel: t-test, 6-day: H929 control (-dox):H929 control (+dox) (P = 0.9316); H929 BRD9 KD#2 (-dox):H929 BRD9 KD#2
(+dox) (P < 0.0001); H929 BRD9 KD#5 (-dox): H929 BRD9 KD#5 (+dox) (P < 0.0003). E, lower left panel Effects of doxycycline-inducible BRD9 KD
on H929 colony formation. 1000 cells/mL/well were seeded; colonies were counted 12 days postseeding. Colonies were counted twice/well.
Data are presented as percent of DMSO-treated (-doxycycline) control wells. E, lower right panel BRD9 expression in H929 control cells and
doxycycline-inducible BRD9 KD H929 cells + /- doxycycline. DOX, 1 µg/ml; DMSO, 0.1%. F Effects of BRD9 degrader treatment on proliferation
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AML, previously identiﬁed as exhibiting BRD9 dependency and
thus serving as a positive reference for comparison with the other
blood cancers we investigated. Speciﬁcally, we examine the
importance of BRD9 for AML cell survival benchmarking a novel
BRD9 degrader against a previously reported BRD9 degrader as
well as BRD9 suppression by KO and KD approaches. Our ﬁndings
reveal a clear BRD9 dependency in AML as well as in two
additional hematologic malignancies, B-ALL and MM. Interestingly
we also observe a consistent lack of response in malignancies of
the T lymphocytic lineage.
Our results show a similar pattern among all three heme
malignancies. For AML, we observe a correlation among several
lines between sensitivity to BRD9 degrader treatment in terms of
inhibition of cell growth and the extent of BRD9 degradation
(MV4-11, SKM-1, Kasumi-1 (sensitive) versus HEL, KO52 (resistant)).
Speciﬁcally, higher concentrations of BRD9 degrader are required
to observe BRD9 degradation and growth inhibition for certain cell
lines, such as HEL and KO52, as compared to other cell lines, such
as MV4-11, SKM-1, and Kasumi-1. We anticipate that this may be
related, at least in part, to differences in the degradation
machinery in each AML cell type. Similarly, we observed a
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correlation between ALL and MM cell line sensitivity to BRD9
degrader treatment and BRD9 degradation, which suggests cellbased degradation mechanisms may be cell context-dependent
and may explain why some transformed cells are more vulnerable
to BRD9 degrader treatment than others.
Importantly, through RNA-seq analysis, we sought to identify
BRD9-regulated signaling pathways among three heme malignancies to understand common and lineage-speciﬁc roles for
BRD9. Pathway analysis revealed numerous uniquely deregulated
genes in cells representing each of the three heme malignancies
following BRD9 degradation. We also observed some common
overlapping signaling pathways related to proliferation, immune
response, inﬂammatory response, cell adhesion, and DNA repair/
replication. This ﬁnding is consistent with deregulated signaling
pathways in AML, but unexplored in the context of non-AML
heme malignancies. These commonalities may be mechanistically
related to the BRD9 dependence shared by these different heme
malignancies and could be potentially exploited for therapy. For
example, including a BRD9 degrader in drug combinations should
be considered for clinical testing and may be effective in front-line
induction of remission. Differentiation-inducing agents, such as
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decitabine and ATRA, are in fact strongly potentiated by BRD9
degrader and inhibitor treatment.
A role for BRD9 in the maintenance of MYC expression in AML
has previously been reported for the mouse RN-2 cell line and
the human NOMO-1 cell line [17]. We observed MYC to be
downregulated in some cell lines, but not in others. In AML,
whereas MYC downregulation correlated with BRD9 degradation in Kasumi-1 and MV4-11 cells, it did not for KO52, HEL and
BRD9 degrader-sensitive SKM-1 cells. Similarly, MYC downregulation correlated with BRD9 degradation in H929 (MM)
cells, but less so for the MM lines, MM.1S and U266. However,
for the ALL cell line, RS4;11, which is inhibited by- BRD9
degraders, a MYC signature was not apparent following BRD9
degrader treatment. Our conclusion is that while BRD9 may play
a role in maintenance of MYC expression in some acute
leukemia and MM cells, it does not play a universal role in
maintenance of MYC expression. Thus, further studies geared
toward gaining a better understanding of the biological
signiﬁcance of a BRD9-MYC axis in heme malignancies are
warranted.
AML has been treated using chemotherapy to induce remissions for decades, and despite advances in molecular characterization of primary and recurrent disease, new drug approvals have
been few. Several recognized subtypes possess additional layers
of heterogeneity that include cytogenetic factors and age of
onset, which make it difﬁcult to deﬁne unique drug targets as
candidates that might induce long-term remissions such as BCRABL in chronic myeloid leukemia (CML). Combinations of drugs
therefore are likely to endure as a mainstay for these patients. In
consideration of genetic and phenotypic heterogeneity, we
employed the use of a drug combination that could offer
increased response rates. We ﬁnd that modulating BRD9
potentiates the effects of numerous agents that are currently
part of the standard treatment regimen for AML and other
hematologic malignancies to induce differentiation and/or cytotoxic outcomes. Particularly robust effects were observed when
combining targeted BRD9 degraders with venetoclax, decitabine,
or ATRA. We also show that primary AML cells that are relatively
resistant to BRD9 degrader treatment as a single agent are killed
to a greater extent when the BRD9 degrader is combined with
standard chemotherapy. Taken together, our ﬁndings support
further development of therapeutic targeting of BRD9, alone or
combined with other agents, as a novel strategy for acute
leukemias and MM.
The studies reported herein reveal a BRD9 dependency in acute
leukemia and MM and highlight its importance for cell growth and
signaling in these diseases. Our ﬁndings also unveil the robust
synergizing potential of selective BRD9 targeting in hematopoietic
malignancies.
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